Wedbush Equities Analysts Lift Earnings Estimates for FENC

Adherex Technologies Inc. (NASDAQ:FENC) – Wedbush raised their Q2 2026 EPS estimates for Adherex Technologies in a report released on Friday, November 14th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $0.39 per share for the quarter, up from their previous forecast of $0.37. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share.

Adherex Technologies (NASDAQ:FENC) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.06. The business had revenue of $12.46 million during the quarter, compared to the consensus estimate of $13.43 million.

Several other equities research analysts also recently issued reports on the company. Zacks Research downgraded Adherex Technologies from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 14th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Adherex Technologies in a research note on Thursday, August 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Adherex Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Craig Hallum boosted their price target on shares of Adherex Technologies from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.33.

Adherex Technologies Stock Up 2.2%

Shares of Adherex Technologies stock opened at $7.86 on Monday. Adherex Technologies has a 52 week low of $3.96 and a 52 week high of $9.92. The business has a 50 day moving average price of $8.69 and a 200-day moving average price of $8.32. The company has a market cap of $220.89 million, a PE ratio of -18.71 and a beta of 0.71.

Insider Activity

In related news, Director Rosty Raykov sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $8.10, for a total transaction of $81,000.00. Following the completion of the sale, the director owned 82,318 shares in the company, valued at approximately $666,775.80. This trade represents a 10.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Southpoint Capital Advisors Lp sold 26,900 shares of Adherex Technologies stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $9.59, for a total transaction of $257,971.00. Following the completion of the sale, the insider directly owned 4,050,314 shares in the company, valued at approximately $38,842,511.26. This represents a 0.66% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 88,889 shares of company stock valued at $831,526. 11.76% of the stock is owned by company insiders.

Institutional Investors Weigh In On Adherex Technologies

A number of hedge funds have recently modified their holdings of FENC. AIGH Capital Management LLC purchased a new position in Adherex Technologies in the first quarter valued at approximately $2,199,000. Nuveen LLC bought a new stake in shares of Adherex Technologies in the first quarter valued at $158,000. AQR Capital Management LLC bought a new stake in shares of Adherex Technologies in the first quarter valued at $66,000. Finally, Jane Street Group LLC purchased a new position in shares of Adherex Technologies during the 1st quarter valued at $90,000. Institutional investors own 55.51% of the company’s stock.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.